(VIANEWS) - Investors were disappointed with Celyad Oncology as shares fell 12.98% to EUR0.59 at 15:23 EST on Thursday. This followed two sessions of declines for the BEL 20, which rose 0.32% at EUR3,652.28, but nevertheless appears to be showing some sign of improvement during today's trading session.
About CELYAD ONCOLOGY
Celyad Oncology SA is a clinical-stage biopharmaceutical company focused on developing CAR-T cell therapies for cancer treatment. Their three lead product candidates CYAD-101, CYAD-211 and CYAD-02 are in various stages of clinical trials for metastatic colorectal cancer; relapsed/refractory multiple myeloma; acute myeloid leukemia myelodysplastic syndromes respectively. Celyad has licensing agreements with Novartis International AG for allogeneic CAR-T cells while Horizon Discovery Group plc offers shRNA reagents. Celyad was founded in 2004 with their headquarters located at Mont-Saint-Guibert Belgium.
Technical Analysis
CELYAD ONCOLOGY stock has seen a significant decrease in volume recently, as today's reported volume was 35.51% below its average daily trading activity of 34,895. This could indicate lack of interest or decreased trading activity - however its volatility has remained relatively consistent over the last week, month, and quarter; with average intraday variations being between 0.75% - 1.69% and 4.24% for each. However, according to CELYAD ONCOLOGY's stochastic oscillator - an indicator used to gauge overbought/oversold conditions - its stock is currently overbought (>=80), suggesting it may be time for a price correction or decrease in value. Keep in mind that stock prices depend on many different factors including company performance, market conditions, investor sentiment analysis etc - before making any investments decisions or taking any actions on them.
Equity Analysis
Earnings per share (EPS) is a financial metric used to measure how much profit a company has generated per outstanding share. Celyad Oncology currently boasts an EPS figure of EUR-1.48 over its trailing twelve month period. Negative earnings per share (EPS) is indicative of a company incurring losses during its last twelve-month period, causing investors to question its profitability and whether to invest in it or not. Investors generally prefer profitable companies; however, investors should carefully evaluate other aspects such as revenue growth, competitive position, and future prospects before making their decision. Investors should also keep an eye out for company guidance and analyst estimates regarding future earnings. If they expect the business to turn profitable soon, investing could be lucrative; otherwise it might be wiser to opt out.
More news about CELYAD ONCOLOGY (CYAD.BR).